In a study of 87 locally advanced HER2 breast cancer patients treated with trastuzumab, 94 % of the patients with high HER2 specific interferon gamma (IFN-g) Th1 immunity had pCR as compared to 33 % of patients that did not achieve pCR (p = 0.0002). The gene discussed is ERBB2; the disease is breast carcinoma.